PATENT CLAIM ANALYSIS

Application Number: 16250278
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "274000"]

Abstract:
The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.

Claim (Index 2):
A process for the manufacture of the compound of formula IA or IB as defined in  claim 1 , which process comprises\n alkylating a compound of formula with ethyliodide and separating of the isomers to a compound of formulas or, if desired, converting the compound obtained into a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 99.0
- Lexical Diversity: 1.1875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15869268', '15707848', '15245955', '15867097', '15205466']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7538887117413628
- 35 USC 102 Novelty (BERT): 0.5348168067802589
- Combined Prediction Score: 0.7319815212452525
- Mean Citation Score: 270.238132
- Max Citation Score: 338.14395
- Similarity Product: 237.9169308083296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test